Current guidelines for palliative treatment of metastatic colorectal cancer (mCRC) patients include treatment with chemotherapy combined with the VEGF‐inhibitor bevacizumab.1, 2. This evidence concerns the gene VEGFA and metastatic colorectal cancer.